SUTRO BIOPHARMA, INC. Deferred Offering Costs
SUTRO BIOPHARMA, INC. (STRO) had Deferred Offering Costs of $0 as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-12
- 2026-06-30: Deferred Offering Costs $0.00.
- 2026-03-31: Deferred Offering Costs $500.00K.
- 2018-12-31: Deferred Offering Costs $0.00.
- 2018-09-30: Deferred Offering Costs $4.60M.
| Period end | Deferred Offering Costs |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-14 |
| 2018-12-31 | $0.00 10-K · filed 2019-04-01 |
| 2018-09-30 | $4.60M 10-Q · filed 2018-11-14 |
| 2017-12-31 | $500.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |